Strategic funding Tactiva has secured substantial grant support totaling about $23 million from NCI SPORE and NYSTEM, signaling strong validation and potential for future grant-driven collaborations or co-development opportunities with research institutions.

Immunotherapy focus As a biotechnology company pursuing next generation adoptive T cell therapy with a dual TCR approach, there are opportunities to position partnerships with larger biotechs and CROs for joint development, trials, or manufacturing collaboration in immuno-oncology.

Strategic investment Significant Series A funding raised in 2018 indicates investor confidence and momentum; BD outreach can target co-investors, strategic pharma partners, and potential licensees interested in novel ACT platforms.

Academic licensing Technology licensed from Roswell Park Institute presents a pathway for tiered collaboration models, including sponsored research, milestone-driven partnerships, or license expansion to de-risk or accelerate late-stage development with larger sponsors.

Early-stage footprint Small team size and revenue under a million suggest lean operations; sales strategies could emphasize CRO/CMO partnerships, contract-based development services, and capacity planning discussions to support scaling and manufacturing readiness.